Bone Dysplasia Sclerosteosis Results from Loss of the SOST Gene Product, a Novel Cystine Knot–Containing Protein
Open accessThe DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Abstract
Sclerosteosis is an autosomal recessive sclerosing bone dysplasia characterized by progressive skeletal overgrowth. The majority of affected individuals have been reported in the Afrikaner population of South Africa, where a high incidence of the disorder occurs as a result of a founder effect. Homozygosity mapping in Afrikaner families along with analysis of historical recombinants localized sclerosteosis to an interval of approximately 2 cM between the loci D17S1787 and D17S930 on chromosome 17q12-q21. Here we report two independent mutations in a novel gene, termed "SOST." Affected Afrikaners carry a nonsense mutation near the amino terminus of the encoded protein, whereas an unrelated affected person of Senegalese origin carries a splicing mutation within the single intron of the gene. The SOST gene encodes a protein that shares similarity with a class of cystine knot-containing factors including dan, cerberus, gremlin, prdc, and caronte. The specific and progressive effect on bone formation observed in individuals affected with sclerosteosis, along with the data presented in this study, together suggest that the SOST gene encodes an important new regulator of bone homeostasis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mutations in genes that have highly enriched expression in osteocytes cause rare bone and mineral disorders.”
From Osteocyte transcriptome mapping identifies a molecular landscape controlling skeletal homeostasis and susceptibility to skeletal disease (2021) · cites this paper as [17]
Citations
Cites
Bone: Formation by Autoinduction
Urist, M. R. (1965) · Science · doi:10.1126/science.150.3698.893 · Cited by 5,546 · cited 1×
“Although this family of morpho-gens was originally identified on the basis of bone-in-ducing activity (Urist 1965), a number of these factors have been shown to be critical for very early stages of embryogenesis and fetal development.”
Prediction of complete gene structures in human genomic DNA
Burge, C., & Karlin, S. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.0951 · Cited by 4,228 · cited 8×
“The novel variant gene (designated “P50gsc3”) predicted by GENSCAN was located between markers D17S951 and D17S1860 (fig.”
InfluentialA comprehensive genetic map of the human genome based on 5,264 microsatellites
Dib, C., Fauré, S., Fizames, C., Samson, D., Drouot, N., Vignal, A., Millasseau, P., Marc, S., Kazan, J., Seboun, E., et al. (1996) · Nature · doi:10.1038/380152a0 · Cited by 2,928 · cited 3×
“D17S1793, D17S1789, D17S951, and D17S1860 within the critical region bounded by D17S1787 and D17S930, an interval of ∼ 2 cM (Dib et al. 1996) on the cytogenetic border between the chromosomal bands 17q12–q21.”
Bone morphogenetic proteins: multifunctional regulators of vertebrate development.
Hogan, B. L. (1996) · Genes & Development · doi:10.1101/gad.10.13.1580 · Cited by 1,962
Therapeutic Approaches to Bone Diseases
Rodan, G. A., & Martin, T. J. (2000) · Science · doi:10.1126/science.289.5484.1508 · Cited by 1,767 · cited 1×
“Currently there is no effective treatment for the restoration of normal bone mass in individuals with pathologically low skeletal density, and there is a large unmet need for therapy that can increase bone deposition in osteoporosis (Rodan and Martin 2000).”
BackgroundEasy calculations of lod scores and genetic risks on small computers.
Lathrop, M. G., & Lalouel, J.-M. (1984) · Europe PMC (PubMed Central) · Cited by 1,526
Faster sequential genetic linkage computations.
Cottingham, R. W., Idury, R. M., & Schäffer, A. A. (1993) · Europe PMC (PubMed Central) · Cited by 1,364
Nonsense-mediated mRNA decayin health and disease
Frischmeyer, P. A. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.10.1893 · Cited by 992 · cited 1×
“The relatively low levels of mutant transcripts observed could be the result of nonsense-mediated mRNA decay, as the inclusion of intronic sequence introduced an in-frame nonsense codon (Frischmeyer and Dietz 1999; Hentze and Kulozik 1999).”
BackgroundHomozygosity Mapping: A Way to Map Human Recessive Traits with the DNA of Inbred Children
Lander, E. S., & Botstein, D. (1987) · Science · doi:10.1126/science.2884728 · Cited by 875
FORMATION AND FUNCTION OF SPEMANN'S ORGANIZER
Harland, R., & Gerhart, J. (1997) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.13.1.611 · Cited by 839 · cited 1×
“In addition, the requirement for the coordinated expression of negative regulators of BMP activity, such as noggin and chordin, as well as members of the dan family, has been well described (Harland and Gerhart 1997; Sasai and De Robertis 1997; Hsu et al. 1998).”
Background
Research works printed but not linked: 3
- Gardner J (1999) Profound childhood deafness in South Africa: a clinical and molecular genetic approach. Ph.D. thesis, University of Cape Town, Cape Town
- Hausen, 1967, Sklerosteose, Vol. 6, 351
- Peitruschka, 1958, Weitere Mitteilungen über die Marmorknochenkrankheit (Albers-Schonbergsche Krankheit) nebst Bemerkungen zur Differentialdiagnose, Klin Monatbl, 132, 509
Cited by
Items 601–700 of 1,000
Cellular Actions of Parathyroid Hormone
Kousteni, S., & Bilezikian, J. P. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373884-4.00049-5 · Cited by 19
Hartung, A., Sieber, C., & Knaus, P. I. (2006) · Signal Transduction · doi:10.1002/sita.200600098 · Cited by 16
Miyamoto, T. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041138 · Cited by 15
“…activation, resulting in increased bone mass [52,53 Mutations in the SOST gene encoding the Sclerostin protein result in a disease that causes increased Mutations in the SOST gene encoding the Sclerostin protein result in a disease that causes increased bone mass [54,55]. bone mass [54,55].”
John, H. C. S., Hansen, S. J., & Pike, J. W. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.09.005 · Cited by 15
“Consistent with the role of sclerostin as a negative regulator of bone formation, both diseases result in thickened bones throughout the body and symptoms such as facial palsy, hearing loss, and vision difficulties can result from hardening bone damaging cranial nerves [7, 8].”
BackgroundAn osteosclerotic form of Robinow syndrome
Bunn, K. J., Lai, A., Al-Ani, A. H., Farella, M., Craw, S., & Robertson, S. P. (2014) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36677 · Cited by 16
Jeon, I., Park, S. B., Moon, B. J., Choi, M., Kuh, S. U., & Kim, J. (2024) · Neurospine · doi:10.14245/ns.2347256.628 · Cited by 15
“22-24 Bisphosphonates (BPs), as antiresorptive agents that work by inhibiting osteoclast-mediated bone resorption, continue to be widely considered and used as one of the treatment options for patients with osteoporosis.”
BackgroundOsteocyte: a Cellular Basis for Mechanotransduction in Bone
Gu, G., Kurata, K., Chen, Z., & Väänänen, K. (2007) · Journal of Biomechanical Science and Engineering · doi:10.1299/jbse.2.150 · Cited by 16
Ryan, Z. C., Craig, T. A., McGee‐Lawrence, M. E., Westendorf, J. J., & Kumar, R. (2014) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2014.11.021 · Cited by 15
“Brunkow et al [7] showed that “sclerosteosis is an autosomal recessive sclerosing bone dysplasia characterized by progressive skeletal overgrowth.”
BackgroundKristianto, J., Johnson, M. G., Afzal, R., & Blank, R. D. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.09.014 · Cited by 18
“Mendelian high bone mass disorders, sclerosteosis and Van Buchem disease, arise as a consequence of mutations in SOST, the gene encoding the WNT antagonist sclerostin.(73,74) Overexpression of the WNT inhibitor DKK1 drives bone resorption in multiple myeloma.”
BackgroundMarkers of Bone and Cartilage Turnover
Woitge, H. W., & Seibel, M. J. (2017) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0043-106438 · Cited by 15
Syndactyly/Brachyphalangy and Nail Dysplasias as Marker Lesions for Sclerosteosis
Itin, P. H., Keserue, B., & Hauser, V. (2001) · Dermatology · doi:10.1159/000051649 · Cited by 15
“Recently, the responsible gene, a novel cystine knot-containing protein, has been found [”
BackgroundKim, S. P., Seward, A. H., Garcia-Diaz, J. G., Alekos, N. S., Gould, N. R., Aja, S. M., Stains, J. P., Wolfgang, M. J., & Riddle, R. C. (2023) · iScience · doi:10.1016/j.isci.2023.106999 · Cited by 17
Sclerostin as a new target of diabetes-induced osteoporosis
Lǐ, Y., Luo, Y., Huang, D., & Peng, L. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1491066 · Cited by 16
Exploiting the WNT Signaling Pathway for Clinical Purposes
Johnson, M. L., & Recker, R. R. (2017) · Current Osteoporosis Reports · doi:10.1007/s11914-017-0357-0 · Cited by 14
Wang, B., Guo, H., Geng, T., Sun, K., Zhang, L., Lu, Z., & Jin, Q. (2021) · Bioscience Reports · doi:10.1042/bsr20203003 · Cited by 16
The Roles of Sclerostin in Immune System and the Applications of Aptamers in Immune-Related Research
Sun, M., Chen, Z., Wu, X., Yu, Y., Wang, L., Lü, A., Zhang, G., & Li, F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.602330 · Cited by 16
“Therefore, it was presumed that sclerostin inhibits bone growth through serving as a BMPs antagonist (26, 27), just like other members of the DAN family.”
BackgroundGenomics drugs in clinical trials
Hall, J., Dennler, P., Haller, S., Pratsinis, A., Säuberli, K., Towbin, H., Walther, K., & Woytschak, J. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd1552-c1 · Cited by 14
Javaheri, B., Herbert, E., Hopkinson, M., Aljazzar, A., & Pitsillides, A. A. (2019) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.12.007 · Cited by 13
Effects of sclerostin antibody on bone healing
Mihara, A., Yukata, K., Seki, T., Iwanaga, R., Nishida, N., Fujii, K., Nagao, Y., & Sakai, T. (2021) · World Journal of Orthopedics · doi:10.5312/wjo.v12.i9.651 · Cited by 15
Paracrine and endocrine functions of osteocytes
Michigami, T. (2022) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.2022-0053 · Cited by 13
Tendon Cells Root Into (Instead of Attach to) Humeral Bone Head via Fibrocartilage-Enthesis
Wang, Z., Ma, C., Chen, D., Haslett, C., Xu, C., Dong, C., Wang, X., Zheng, M., Jing, Y., & Feng, J. Q. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.79007 · Cited by 15
“Importantly, we observed a noticeable SOST signal (a classic osteocyte marker [42], also a well-documented Wnt signaling inhibitor [45]), in the 3.”
Antisclerostin Effect on Osseointegration and Bone Remodeling
Couto, B. A. D. A., Fernandes, J. C. H., Saavedra-Silva, M., Roca, H., CASTILHO, R. M., & Fernandes, G. V. O. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041294 · Cited by 14
“Sclerostin is a glycoprotein encoded in humans by the SOST gene [1,2].”
BackgroundNovel SOST gene mutation in a sclerosteosis patient from Morocco: A case report
Belkhribchia, M. R., Collet, C., Laplanche, J., & Hassani, R. (2014) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2014.02.007 · Cited by 13
“, 2001, 2005], and three nonsense mutations [Balemans et al., 2001; Brunkow et al., 2001; Kim et al., 2008] (Table 1).”
BackgroundSclerosing Bone Dysplasias: Leads Toward Novel Osteoporosis Treatments
Fijałkowski, I., Boudin, E., Mortier, G. R., & Hul, W. V. (2014) · Current Osteoporosis Reports · doi:10.1007/s11914-014-0220-5 · Cited by 13
Lewiecki, E., Baron, R., Bilezikian, J., Gagel, R. E., Leonard, M., Leslie, W., Mcclung, M., & Miller, P. D. (2015) · Journal of clinical densitometry · doi:10.1016/j.jocd.2015.11.003 · Cited by 12
“an analog of PTH-related peptide (PTHrP [1–34]),”
Sclerostin antibody inhibits skeletal deterioration in mice exposed to partial weight-bearing
Spatz, J., Ellman, R., Cloutier, A., Louis, L. D., van Vliet, M., Dwyer, D., Stolina, M., Ke, H. Z., & Bouxsein, M. (2017) · Life Sciences in Space Research · doi:10.1016/j.lssr.2017.01.001 · Cited by 13
Romosozumab Treatment Converts Trabecular Rods into Trabecular Plates in Male Cynomolgus Monkeys
Matheny, J. B., Torres, A. M., Ominsky, M. S., & Hernandez, C. J. (2017) · Calcified Tissue International · doi:10.1007/s00223-017-0258-3 · Cited by 15
Suppression of Sclerostin and Dickkopf-1 levels in patients with fluorine bone injury
Wang, W., Xu, J., Liu, K., Liu, X., Li, C., Cui, C., Zhang, Y., & Li, H. (2013) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2013.01.005 · Cited by 13
Kurgan, N., Stoikos, J., Baranowski, B. J., Yumol, J., Dhaliwal, R., Sweezey-Munroe, J. B., Fajardo, V. A., Gittings, W., Macpherson, R. E. K., & Klentrou, P. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4768 · Cited by 12
“Despite sclerostin not being highly expressed by adipose tissue (AT),((5,7))”
BackgroundRegulation of the Osteocyte Secretome with Aging and Disease
Kitase, Y., & Prideaux, M. (2023) · Calcified Tissue International · doi:10.1007/s00223-023-01089-w · Cited by 14
The role of sclerostin in lipid and glucose metabolism disorders
Jiang, H., Li, D., Han, Y., Li, N., Tao, X., Liu, J., Zhang, Z., Yu, Y., Wang, L., Yu, S., et al. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115694 · Cited by 13
Genetics of Skeletal Disorders
Hannan, F. M., Newey, P. J., Whyte, M. P., & Thakker, R. V. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_350 · Cited by 13
Duren, D. L., Blangero, J., Sherwood, R. J., Šešelj, M., Dyer, T. D., Cole, S. A., Lee, M., Choh, A. C., Chumlea, W. C., Siervogel, R. M., et al. (2011) · Bone · doi:10.1016/j.bone.2011.08.024 · Cited by 12
“Mutations in the gene that prevent sclerostin production result in sclerosteosis, a condition characterized by high bone mass throughout the body [68].”
Suoranta, S., Manninen, H. I., Koskenkorva, P., Könönen, M., Laitinen, R., Lehesjoki, A., Kälviäinen, R. K., & Vanninen, R. (2012) · Bone · doi:10.1016/j.bone.2012.08.123 · Cited by 12
“2005 [34] Skull X-rays, DXA 25 Rare, condition occurs mainly in Afrikaners Generalized bone disease Progressive bone thickening and sclerosis of the skeleton, especially of the skull, thickening of the skull is also seen in (healthy) heterozygous carriers SOST [70] AR”
BackgroundYang, Y., Shuai, B., Shen, L., Xu, X.-J., Ma, C., & Lv, L. (2015) · Journal of Huazhong University of Science and Technology [Medical Sciences] · doi:10.1007/s11596-015-1464-8 · Cited by 12
The BMP-2 mutant L51P: a BMP receptor IA binding-deficient inhibitor of noggin
Khattab, H. M., Kubota, S., Takigawa, M., Kuboki, T., & Sebald, W. (2018) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-018-0925-0 · Cited by 13
Genetics and Genomics of SOST: Functional Analysis of Variants and Genomic Regulation in Osteoblasts
Martínez‐Gil, N., Roca‐Ayats, N., Cozar, M., García‐Giralt, N., Ovejero, D., Nogués, X., Grinberg, D., & Balcells, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020489 · Cited by 14
Rare germline variants in individuals diagnosed with schizophrenia within multiplex families
Li, S., DeLisi, L. E., & McDonough, S. I. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.114038 · Cited by 12
Wang, L., Wu, H., Xu, Y., Deng, M., Han, X.-L., & Bai, D. (2015) · Renal Failure · doi:10.3109/0886022x.2015.1077323 · Cited by 12
“Until detection of SOST gene expression in kidney, lung, heart, aorta, as well as dimeric sclerostin protein existence in non-skeletal soft tissues, it is suggested that SOST/sclerostin widely exists in tissues and cells.(10,11)”
BackgroundInhibiting the Inhibitor: A New Route to Bone Anabolism
Jilka, R. L. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090228 · Cited by 12
Bone Morphogenetic Protein Receptors and Actions
Miyazono, K., & Shimanuki, T. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373884-4.00069-0 · Cited by 18
Rentsch, C. A., Cecchini, M. G., & Thalmann, G. N. (2009) · Swiss Medical Weekly · doi:10.4414/smw.2009.12284 · Cited by 16
Patel, M. A., Fraser, D. D., Daley, M., Cepinskas, G., Veraldi, N., & Grazioli, S. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00806-x · Cited by 11
“SOST is a negative regulator for bone metabolism [89–92] and is also elevated in the MIS-C cohort, but its expression decreases by PICU Day 3.”
BackgroundZhang, H., He, J. W., Wang, C., Zhang, Z. L., Yue, H., Hu, W. W., Gu, J., Hu, Y., Li, M., Fu, W. Z., et al. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2832-0 · Cited by 12
“Although the crucial roles of LRP5 and LRP6 in mediating SOST activity has been establish, other SOST interacting proteins are identified to regulate specific aspects of skeletal development such as LRP4 [24, 25] and BMP signaling pathway [26].”
BackgroundRegulation of Wnt signaling by non-coding RNAs during osteoblast differentiation
Saranya, I., Akshaya, R. L., & Selvamurugan, N. (2022) · Differentiation · doi:10.1016/j.diff.2022.10.003 · Cited by 11
Almansouri, A. Y., Abdulfatah, M. E., Baaqil, O. H., Bakheet, A. A., Turki, S., Kotb, M. M., Althubaiti, A., Almaghrabi, M. M., Althubaiti, A. M., Madani, B., et al. (2016) · Journal of Bone Metabolism · doi:10.11005/jbm.2016.23.1.16 · Cited by 11
“[12] Sclerostin is a glycoprotein that is specifically released by osteocytes and is a potent inhibitor of the Wnt/β-catenin signaling pathway, osteoblastic differentiation, and therefore of bone formation.[6-10] Sclerostin, encoded by the gene sclerosteosis (SOST), has been recognized to be a mediator of the immune s…”
BackgroundSelected Works in Bioinformatics
Xia, X. (2011) · InTech eBooks · doi:10.5772/785 · Cited by 11
A Novel Loss-of-Sclerostin Function Mutation in a First Egyptian Family with Sclerosteosis
Fayez, A. G., Aglan, M., Esmaiel, N. N., Zanaty, T. E., Kader, M. A., & Ruby, M. O. E. (2015) · BioMed Research International · doi:10.1155/2015/517815 · Cited by 11
“[14], in which mutations in the coding region of the SOST gene were found in cases of sclerosteosis but not in cases of VBCH.”
BackgroundGupta, A., Välimäki, V., Välimäki, M. J., Löyttyniemi, E., Richard, M., Bukka, P. L., Goltzman, D., & Karaplis, A. C. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0886 · Cited by 12
Sclerosing bone dysplasias: neurologic assessment and management
Hofmeyr, L. M., & Hamersma, H. A. (2004) · Current Opinion in Otolaryngology & Head & Neck Surgery · doi:10.1097/01.moo.0000134441.84110.9e · Cited by 11
Self-citationBone morphogenetic protein receptors and their nuclear effectors in bone formation
Korchynskyi, O., & ten Dijke, P. (2002) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8121-0_3 · Cited by 20
Sclerostin inhibition in rare bone diseases: Molecular understanding and therapeutic perspectives
Xiaohui, T., Wang, L., Yang, X., Jiang, H., Zhang, N., Zhang, H., Li, D., Li, X., Zhang, Y., Wang, S., et al. (2024) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2024.05.004 · Cited by 10
“Sclerostin is a bone tissue-specific inhibitor of the Wnt/ β -catenin pathway, secreted by osteocytes, negatively regulating osteogenic differentiation and bone formation, and promoting osteoclastogenesis and bone resorption [1,2, 92 – 94].”
BackgroundVerifying the effectiveness of romosozumab re-administration on bone mineral density
Kobayakawa, T., & Nakamura, Y. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae196 · Cited by 12
The systemic effects of sclerostin overexpression using ΦC31 integrase in mice
Zhang, D., Park, B. M., Kang, M., Nam, H. J., Kim, E. J., Bae, C. H., & Lim, S. K. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.01.178 · Cited by 11
When a pedodontic examination leads to the diagnosis of osteopetrosis: A case report
Athanasiadou, E., Vlachou, C., Theocharidou, A., Tilaveridis, I., Vargiami, E. G., Antoniadis, K., & Arapostathis, K. N. (2019) · Special Care in Dentistry · doi:10.1111/scd.12427 · Cited by 10
Bariatric Surgery and Bone Loss: Do We Need to Be Concerned?
Brzozowska, M. M., Sainsbury, A., Eisman, J. A., & Baldock, P. A. J. (2014) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-014-9162-9 · Cited by 12
“provided in the human disorders of Van Buchem’s disease [225] and sclerosteosis [226], which exhibit loss of sclerostin expression and pathologically high bone mass.”
BackgroundZhao, J., Xia, W., Nie, M., Zheng, X. S., Wang, Q., Wang, X., Wang, W., Ning, Z., Huang, W., Jiang, Y., et al. (2012) · Bone · doi:10.1016/j.bone.2012.01.003 · Cited by 10
“Many genes in which mutations result in rare bone diseases are also contributors to the variation in BMD in the general population, examples including SOST [21–23], LRP5 [24,25] and CLCLN7 [26,27].”
BackgroundSclerostin–erbB-3 interactions: Modulation of erbB-3 activity by sclerostin
Craig, T. A., & Kumar, R. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.10.048 · Cited by 10
“Human subjects with the sclerosing bone dysplasias, sclerosteosis and van Buchem disease, either lack, or have reduced expression of sclerostin, as a result of stop mutations or splice abnormalities in the SOST gene, or a mutation within an enhancer downstream of the coding region of the SOST gene [2;3;4].”
BackgroundAntitumor Effect of Sclerostin against Osteosarcoma
Ideta, H., Yoshida, K., Okamoto, M., Sasaki, J., Kito, M., Aoki, K., Yoshimura, Y., Suzuki, S.-I., Tanaka, A., Takazawa, A., et al. (2021) · Cancers · doi:10.3390/cancers13236015 · Cited by 11
Campopiano, M. C., Fogli, A., Michelucci, A., Mazoni, L., Longo, A., Borsari, S., Pardi, E., Benelli, E., Sardella, C., Pierotti, L., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.918682 · Cited by 11
“Age at diagnosis Mean [Range] 34 years [10-68] 9 and 59 years 56, 62 years 35 years 42 years [6-74] 39 years [10-80]”
BackgroundGot WNTS? Insight into bone health from a WNT perspective
Craig, S. E. L., Michalski, M. N., & Williams, B. O. (2023) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/bs.ctdb.2023.01.004 · Cited by 10
Sclerosteosis caused by a novel nonsense mutation of SOST in a consanguineous family
He, W., Chen, C., Pan, C., Zhang, M., Yu, X., Wang, D. W., & Hu, S. (2015) · Clinical Genetics · doi:10.1111/cge.12655 · Cited by 11
“The sclerostin protein share highly conserved sequence across the vertebrate species (10).”
BackgroundExpression of sclerostin in the developing zebrafish (Danio rerio) brain and skeleton
McNulty, M. S., Bedell, V. M., Greenwood, T. M., Craig, T. A., Ekker, S. C., & Kumar, R. (2012) · Gene Expression Patterns · doi:10.1016/j.gep.2012.04.003 · Cited by 10
“A loss or reduction in expression of the protein, results in the bone dysplasias, sclerosteosis or van Buchem disease (Balemans et al., 2001; Balemans et al., 2002; Brunkow et al., 2001).”
InfluentialSclerosteosis (craniotubular hyperostosis-syndactyly) with complex hyperphalangy of the index finger
Yagi, H., Takagi, M., Hasegawa, Y., Kayserili, H., & Nishimura, G. (2015) · Pediatric Radiology · doi:10.1007/s00247-015-3292-1 · Cited by 10
Sclerostin serum levels in patients with systemic autoimmune diseases
Fernández-Roldán, C., Genre, F., López‐Mejías, R., Ubilla, B., Mijares, V., Sánchez‐Cano, D., Robles, C. L., Callejas-Rubio, J. L., Ríos-Fernández, R., Ruíz, M. E., et al. (2016) · BoneKEy Reports · doi:10.1038/bonekey.2016.2 · Cited by 10
“Sclerostin was discovered in 2001 from the genetic and molecular study of two rare sclerosing dysplasias, sclerosteosis and van Buchem disease, in which there is absence or decreased gene expression of this protein.(1,2) Sclerostin is a 190 amino-acid glycoprotein secreted mainly, but not exclusively, by mature osteoc…”
BackgroundCardiovascular Safety of Anti-Sclerostin Therapy in Chronic Kidney Disease
Cejka, D. (2021) · Metabolites · doi:10.3390/metabo11110770 · Cited by 10
Sclerosing bone dysplasias with involvement of the craniofacial skeleton
Waterval, J. J., Borra, V., Hul, W. V., Stokroos, R. J., & Manni, J. J. (2013) · Bone · doi:10.1016/j.bone.2013.12.003 · Cited by 11
Modeling craniofacial and skeletal congenital birth defects to advance therapies
Neben, C. L., Roberts, R. R., Dipple, K. M., Merrill, A. E., & Klein, O. D. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw171 · Cited by 10
Song, J., Chang, W., Wang, Y., Gao, P., Zhang, J., Xiao, Z., An, F., & Yan, C. (2024) · Biomolecules and Biomedicine · doi:10.17305/bb.2024.11200 · Cited by 11
Pérez-Campo, F. M., Sañudo, C., Delgado‐Calle, J., Arozamena, J., Zarrabeitia, M. T., & Riancho, J. A. (2014) · Calcified Tissue International · doi:10.1007/s00223-014-9880-5 · Cited by 9
“Although SOST mRNA is expressed in many tissues during embryogenesis (heart, liver and kidney) [6–8], its postnatal expression in adult human tissues is largely”
BackgroundYambe, S., Yoshimoto, Y., Ikeda, K., Maki, K., Takimoto, A., Tokuyama, A., Higuchi, S., Yu, X., Uchibe, K., Miura, S., et al. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1360041 · Cited by 9
Sclerostin regulation: a promising therapy for periodontitis by modulating alveolar bone
Li, T., Wang, R., Li, Q., Li, C., & Jiang, L. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000764 · Cited by 9
“Introduction previously been researched in several diseases such as osteoporosis, sclerosteosis, and van Buchem disease.([3-5]) In As of 2016, severe periodontitis was the eleventh most prevalent epidemic disease in the world, which contributes to progressive alveolar bone destruction.”
BackgroundLRP4 LDLα repeats of astrocyte enhance dendrite arborization of the neuron
Yan, M., Guo, A., Chen, P., Jing, H., Ren, D., Zhong, Y., Wu, Y., Fei, E., Lai, X., Zou, S., et al. (2020) · Molecular Brain · doi:10.1186/s13041-020-00708-z · Cited by 9
Sclerostin: how human mutations have helped reveal a new target for the treatment of osteoporosis
Robinson, M. K., Caminis, J. N., & Brunkow, M. E. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.04.001 · Cited by 9
Self-citationHow rare bone diseases have informed our knowledge of complex diseases
Johnson, M. L. (2016) · BoneKEy Reports · doi:10.1038/bonekey.2016.69 · Cited by 9
Diao, X., Li, Z., An, B., Xin, H., Wu, Y., Li, K., Feng, F., & Dou, C. (2017) · Scientific Reports · doi:10.1038/s41598-017-06867-9 · Cited by 9
Albiol, L., Cilla, M., Pflanz, D., Krämer, I., Kneissel, M., Duda, G. N., Willie, B. M., & Checa, S. (2018) · Journal of The Royal Society Interface · doi:10.1098/rsif.2018.0012 · Cited by 9
Tobias, J. H., Duncan, E. L., Kague, É., Hammond, C. L., Gregson, C. L., Bassett, D., Williams, G. R., Min, J. L., Gaunt, T. R., Karasik, D., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.630875 · Cited by 9
“Sclerostin, encoded by SOST, was initially identified from the study of patients with the heritable HBM disorder, sclerosteosis (6).”
Backgroundvan Bezooijen, R. L., Papapoulos, S. E., Hamdy, N. A. T., & Löwik, C. W. G. M. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373884-4.00014-8 · Cited by 9
TIEG1-NULL OSTEOCYTES DISPLAY DEFECTS IN THEIR MORPHOLOGY, DENSITY AND SURROUNDING BONE MATRIX
Haddad, O., Hawse, J. R., Subramaniam, M., Spelsberg, T. C., & Bensamoun, S. F. (2009) · Journal of Musculoskeletal Research · doi:10.1142/s0218957709002304 · Cited by 9
Porcupine inhibition is a promising pharmacological treatment for severe sclerosteosis pathologies
Dreyer, T. J., Keen, J. A. C., Wells, L. M., Hopkinson, M., Orriss, I. R., Holdsworth, G., Pitsillides, A. A., & Roberts, S. J. (2025) · Bone Research · doi:10.1038/s41413-025-00406-3 · Cited by 8
“17,67 It would thus be fi tting that sclerosteosis patients should also now bene fi t from the understanding of bone biology which their condition has helped to acquire.”
Huybrechts, Y., Boudin, E., Hendrickx, G., Steenackers, E., Hamdy, N. A. T., Mortier, G. R., Diaz‐Guerra, G. M., Bracamonte, M. S., Appelman‐Dijkstra, N. M., & Hul, W. V. (2021) · Genes · doi:10.3390/genes13010080 · Cited by 8
Arai, M., Ochi, H., Sunamura, S., Ito, N., Nangaku, M., Takeda, S., & Sato, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713633 · Cited by 9
LRP5 promotes adipose progenitor cell fitness and adipocyte insulin sensitivity
Loh, N. Y., Vasan, S. K., Rosoff, D. B., Roberts, E., van Dam, A. D., Verma, M., Phillips, D., Wesolowska‐Andersen, A., Neville, M. J., Noordam, R., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-00774-1 · Cited by 8
Innovations thérapeutiques dans l’ostéoporose (anticorps antisclérostine et denosumab)
Quemerais, M. A., Kerlan, V., & Chabre, O. (2011) · Annales d Endocrinologie · doi:10.1016/s0003-4266(11)70005-1 · Cited by 12
“La sclérostine est le produit du gène SOST identifi é par l’analyse génétique de sujets atteints d’une forme familiale d’hyperostose [15-17].”
BackgroundSecreted noncollagenous proteins of bone
Gorski, J. P., & Hankenson, K. D. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814841-9.00015-4 · Cited by 8
Sclerostin and Its Involvement in the Pathogenesis of Idiopathic Scoliosis
Vasiliadis, E. S., Evangelopoulos, D. S., Kaspiris, A., Vlachos, C., & Pneumaticos, S. G. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10225286 · Cited by 9
Metabolism and Endocrine Disorders: What Wnt Wrong?
Franco, C. N., Noe, M. M., & Albrecht, L. V. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.887037 · Cited by 8
Nakamura, K., Koide, M., Kobayashi, Y., Yamashita, T., Matsushita, M., Yasuda, H., Ishihara, Y., Yoshinari, N., & Udagawa, N. (2023) · Journal of Periodontal Research · doi:10.1111/jre.13134 · Cited by 8
Wnts’ fashion statement: from body stature to dysplasia
Malhotra, D., & Yang, Y. (2014) · BoneKEy Reports · doi:10.1038/bonekey.2014.36 · Cited by 9
van Bezooijen, R. L., Papapoulos, S. E., Hamdy, N. A. T., ten Dijke, P., & Löwik, C. W. G. M. (2005) · BoneKEy-Osteovision · doi:10.1138/20050189 · Cited by 13
“Based on amino acid sequence similarity, sclerostin was suggested to be a member of the DAN family of glycoproteins (9).”
BackgroundMolecular mediators and controlling mechanism of vascular calcification
Melaku, L. S., & Mossie, A. (2017) · International Journal of Clinical and Experimental Physiology · doi:10.4103/ijcep.ijcep_3_17 · Cited by 8
Osteocyte mechanosensing following short-term and long-term treatment with sclerostin antibody
Morrell, A. E., Robinson, S. T., Ke, H. Z., Holdsworth, G., & Guo, X. E. (2021) · Bone · doi:10.1016/j.bone.2021.115967 · Cited by 8
Insight into the WNT system and its drug related response
Tamanini, S., Idolazzi, L., Gatti, D., Viapiana, O., Fassio, A., & Rossini, M. (2013) · Reumatismo · doi:10.4081/reumatismo.2013.219 · Cited by 8
Expression and regulation of the SOST gene
Qin, L., Da-Xia, D. I. N. G., Lu-Lu, C. U. I., & Huang, Q. (2013) · Hereditas (Beijing) · doi:10.3724/sp.j.1005.2013.00939 · Cited by 8
“Baleman等([3])和Brunkow等([4])对该区域进行定位克隆 和测序发现了致病基因 SOST(Sclerostin), 其编码的”
BackgroundAlzahrani, M. M., Makhdom, A. M., Rauch, F., Lauzier, D., Kotsiopriftis, M., Ghadakzadeh, S., & Hamdy, R. C. (2017) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-017-0847-2 · Cited by 8
“Clinically, the loss of function of the gene coding for sclerostin (SOST) leads to sclerosteosis in humans, a disorder characterized by high bone mass [12, 13].”
BackgroundNishimura, G., Hasegawa, T., Kinoshita, E., Tanaka, Y., Kurosawa, K., & Yoshimoto, M. (2004) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.30030 · Cited by 8
“, 1996] functional loss of SOST in sclerosteosis [Balemans et al., 2001; Brunkow et al., 2001], haploinsufficiency of NSD1 in Sotos syndrome (MIM 117550) [Kurotaki et al.”
BackgroundGenetic Determinants of Bone Mass and Osteoporotic Fracture
Ralston, S. H. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373884-4.00009-4 · Cited by 9
Cardiovascular Safety and Romosozumab—The Plot Thickens
Farr, J. N. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae313 · Cited by 8
Osteogenesis imperfecta: pathogenesis, classification, and treatment
Hasegawa, K. (2025) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.2025-0009 · Cited by 7
Metadata
- Authors
- Brunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., Alisch, R. S., Gillett, L., Colbert, T., Tacconi, P., Galas, D., Hamersma, H., Beighton, P., & Mulligan, J. T.
- Affiliations
- University of Cape Town (ZA)
- University of Cagliari (IT)
- Corresponding author
- Brunkow, Mary E.
- ORCID
- Venue
- The American Journal of Human Genetics
- Publisher
- Elsevier BV
- Published
- 2001-03
- Volume
- 68
- Issue
- 3
- Pages
- 577-589
- ISSN
- 0002-9297 (ISSN-L)
- PMC
- PMC1274471
- OpenAlex
- W2037750372
- Cited by
- 1,011
- References
- 50
- Citations by year
- 2026: 24 · 2025: 21 · 2024: 32 · 2023: 27 · 2022: 36 · 2021: 53 · 2020: 52 · 2019: 46 · 2018: 50 · 2017: 56 · 2016: 65 · 2015: 61 · 2014: 58 · 2013: 60 · 2012: 56
- FWCI
- 7.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 4523 d)
- Locations
- The American Journal of Human Genetics (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Dermatological and Skeletal Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Connective tissue disorders research
- Keywords
- sclerosteosis, SOST gene, skeletal dysplasia, cystine knot proteins, bone homeostasis, skeletal overgrowth, nonsense mutation, splicing mutation, founder effect, Afrikaner population, bone formation regulation
- MeSH terms
- Amino Acid Sequence, Animals, Base Sequence, Bone Diseases, Chromosome Mapping, Chromosomes, Human, Pair 17, Consanguinity, Cystine, Female, Genetic Markers, Homozygote, Humans, Male, Molecular Sequence Data, Netherlands, Pedigree, Proteins, Recombination, Genetic, Sclerosis, Senegal, South Africa, Conserved Sequence, Alternative Splicing, Bone Morphogenetic Proteins, Mutation, Missense, Black People, White People, Adaptor Proteins, Signal Transducing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.